Aridis Pharmaceuticals, Inc. (ARDS)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Eric J. Patzer Ph.D. | Founder & Executive Chairman | 240k | -- | 1949 |
Dr. Vu L. Truong Ph.D. | Founder, CEO, Chief Scientific Officer & Director | 631.65k | -- | 1964 |
Dr. Hasan Jafri M.D. | Chief Medical Officer | 559.36k | -- | 1967 |
Ms. Tamara S. Allen | Vice President of Finance | -- | -- | 1967 |
Mr. Jeffrey J. Fessler Esq., J.D. | Acting General Counsel | -- | -- | 1963 |
Aridis Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 37
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Corporate Governance
Recent Events
- Jan 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 18, 2023DEFA14A: Proxy StatementsSee Full Filing
- Dec 15, 2023DEFA14A: Proxy StatementsSee Full Filing
- Nov 06, 202310-Q: Periodic Financial ReportsSee Full Filing
- Nov 03, 20238-K: Corporate Changes & Voting MattersSee Full Filing